Open Nav

Please submit your session questions in advance.

Market Outlook-Taking the Temperature of the IPO Market in an Era of Large Pharma M&A

  • Megan Zweig, Rock Health,
  • Jim Healy, Sofinnova,
  • Greg Wade, BTIG,
  • John Kollins, Satsuma Pharmaceuticals, Inc.,
  • Sara Michelmore, MacDougall,
  • Siobhan Pomeroy, Gilead Sciences

As we start to close out 2019, the mixed signals regarding the appetite for IPOs are off from 2018’s strong finish. This year’s 33 offerings in the 1H have totaled $2.992 billion, compared to the $3.484 billion seen in the 35 offerings from last year. Large pharma M&A deals, however, continue to surprise and raise questions about a temporary market shift or a lasting trend. With market volatility also on the rise aided by continued global trade tensions, the second half of 2019 raises concerns about the endurance of high valuations. This session will examine the path forward while highlighting the availability of quality targets in the market.

  • Date:Wednesday, October 23
  • Time:4:00 PM - 4:55 PM
  • Session Type:Educational Session
  • Session Location:California East
Megan Zweig
Rock Health
Jim Healy
Greg Wade
John Kollins
Satsuma Pharmaceuticals, Inc.
Sara Michelmore
Siobhan Pomeroy
Gilead Sciences